The regulation of vascular tetrahydrobiopterin bioavailability

Vascular Pharmacology

Volumn 58, Issue 3, 2013, Pages 219-230

  Starr, Anna ^a   Hussein, Dania ^a   Nandi, Manasi ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Endothelial; GTP cyclohydrolase 1; Nitric oxide synthase; Tetrahydrobiopterin

Indexed keywords

ASCORBIC ACID; BIOMARIN; GCH1 FEEDBACK REGULATORY PROTEIN; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REGULATOR PROTEIN; SAPROPTERIN; SEPIAPTERIN; SUPEROXIDE DISMUTASE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLEX FORMATION; CORONARY ARTERY DISEASE; DNA MODIFICATION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPHENYLALANINEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; VASOSPASTIC ANGINA;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOPTERIN; CARDIOVASCULAR DISEASES; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS;

EID: 84875367037     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.08.002     Document Type: Article

References (196)

1. Alderton W.K., Cooper C.E., Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 2001, 357(Pt. 3):593-615.
2. Alp N.J., et al. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24(3):445-450.
3. Antoniades C., et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114(11):1193-1201.
4. Antoniades C., et al. GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. J. Am. Coll. Cardiol. 2008, 52(2):158-165.
5. Auerbach G., et al. Zinc plays a key role in human and bacterial GTP cyclohydrolase I. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(25):13567-13572.
6. Baek K.J., et al. Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. J. Biol. Chem. 1993, 268(28):21120-21129.
7. Bahrami S., et al. Protection against endotoxemia in rats by a novel tetrahydrobiopterin analogue. Shock 2000, 13(5):386-391.
8. Bartholome K. Letter: a new molecular defect in phenylketonuria. Lancet 1974, 2(7896):1580.
9. Bec N., et al. Reaction of neuronal nitric-oxide synthase with oxygen at low temperature. Evidence for reductive activation of the oxy-ferrous complex by tetrahydrobiopterin. J. Biol. Chem. 1998, 273(22):13502-13508.
10. Bhagat K., Hingorani A., Vallance P. Flow associated or flow mediated dilatation? More than just semantics. Heart 1997, 78(1):7-8.
11. Bleys J., et al. Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2006, 84(4):880-887. (quiz 954-5).
12. Boerma E.C., Koopmans M., Konijn A., Kaiferova K., Bakker A.J., van Roon E.N., Buter H., Bruins N., Egbers P.H., Gerritsen R.T., Koetsier P.M., Kingma W.P., Kuiper M.A., Ince C. Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: A double-blind randomized placebo controlled trial. Crit Care Med. 2010, 38:93-100.
13. Bohme G.A., et al. Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(19):9191-9194.
14. Bommel H.M., et al. Anti-pterins as tools to characterize the function of tetrahydrobiopterin in NO synthase. J. Biol. Chem. 1998, 273(50):33142-33149.
15. Burton B.K., et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J. Inherit. Metab. Dis. 2007, 30(5):700-707.
16. Cai S., et al. GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc. Res. 2002, 55(4):838-849.
17. Chalupsky K., Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(25):9056-9061.
18. Channon K.M. Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc. Med. 2004, 14(8):323-327.
19. Chavan B., et al. GTP cyclohydrolase feedback regulatory protein controls cofactor 6-tetrahydrobiopterin synthesis in the cytosol and in the nucleus of epidermal keratinocytes and melanocytes. J. Invest. Dermatol. 2006, 126(11):2481-2489.
20. Chen H., et al. High-dose oral vitamin C partially replenishes vitamin C levels in patients with type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am. J. Physiol. Heart Circ. Physiol. 2006, 290(1):H137-H145.
21. Cooke J.P., et al. Antiatherogenic effects of l-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 1992, 90(3):1168-1172.
22. Cosentino F., Katusic Z.S. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995, 91(1):139-144.
23. Cosentino F., et al. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart 2008, 94(4):487-492.
24. Costigan M., Latremoliere A., Woolf C.J. Analgesia by inhibiting tetrahydrobiopterin synthesis. Curr. Opin. Pharmacol. 2012, 12(1):92-99.
25. Crabtree, M.J. and Channon, K.M., in press, Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric Oxide, Corrected Proof.
26. Crabtree M.J., et al. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am. J. Physiol. Heart Circ. Physiol. 2008, 294(4):H1530-H1540.
27. Crabtree M.J., et al. Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways. J. Biol. Chem. 2009, 284(41):28128-28136.
28. Crabtree M.J., Hale A.B., Channon K.M. Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency. Free Radic. Biol. Med. 2011, 50(11):1639-1646.
29. Crabtree M.J., Hale A.B., Channon K.M. Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency. Free Radic. Biol. Med. 2011, 50(11):1639-1646.
30. Crabtree, M.J., A.B. Hale, and K.M. Channon, Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency. Free Radic. Biol. Med. 50(11): p. 1639-46.
31. Crane B.R., et al. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science 1998, 279(5359):2121-2126.
32. Cunnington C., Channon K.M. Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart 2010, 96(23):1872-1877.
33. Cunnington C., et al. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation 2012, 125(11):1356-1366.
34. Daiber A., et al. Nitrate tolerance as a model of vascular dysfunction: roles for mitochondrial aldehyde dehydrogenase and mitochondrial oxidative stress. Pharmacol. Rep. 2009, 61(1):33-48.
35. Davidson D., et al. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics 1999, 104(2 Pt. 1):231-236.
36. De Backer D., Creteur J., Preiser J.C., Dubois M.J., Vincent J.L. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002, 166:98-104.
37. Doehring A., et al. Clinical genetics of functionally mild non-coding GTP cyclohydrolase 1 (GCH1) polymorphisms modulating pain and cardiovascular risk. Mutat. Res. 2008, 659(3):195-201.
38. Du Y.H., et al. Endothelium-specific GTP cyclohydrolase I overexpression attenuates blood pressure progression in salt-sensitive low-renin hypertension. Circulation 2008, 117(8):1045-1054.
39. Du J., et al. The protein partners of GTP cyclohydrolase I in rat organs. PLoS One 2012, 7(3):e33991.
40. Dumitrescu C., et al. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(38):15081-15086.
41. d'Uscio L.V., et al. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ. Res. 2003, 92(1):88-95.
42. Eskurza I., et al. Tetrahydrobiopterin augments endothelium-dependent dilatation in sedentary but not in habitually exercising older adults. J. Physiol. 2005, 568(Pt. 3):1057-1065.
43. Fiege B., et al. Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol. Genet. Metab. 2004, 81(1):45-51.
44. Francis B.N., Wilkins M.R., Zhao L. Tetrahydrobiopterin and the regulation of hypoxic pulmonary vasoconstriction. Eur. Respir. J. 2010, 36(2):323-330.
45. Franco Mdo C., et al. Tetrahydrobiopterin improves endothelial dysfunction and vascular oxidative stress in microvessels of intrauterine undernourished rats. J. Physiol. 2004, 558(Pt. 1):239-248.
46. Fukuda Y., et al. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart 2002, 87(3):264-269.
47. Fukuda Y., et al. Tetrahydrobiopterin improves coronary endothelial function, but does not prevent coronary spasm in patients with vasospastic angina. Circ. J. 2002, 66(1):58-62.
48. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288(5789):373-376.
49. Gao L., et al. Mechanistic insights into folic acid-dependent vascular protection: dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: a novel HPLC-based fluorescent assay for DHFR activity. J. Mol. Cell. Cardiol. 2009, 47(6):752-760.
50. Garcia-Cardena G., et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998, 392(6678):821-824.
51. Garry A., et al. Ascorbic acid and tetrahydrobiopterin potentiate the EDHF phenomenon by generating hydrogen peroxide. Cardiovasc. Res. 2009, 84(2):218-226.
52. Gorren A.C., et al. Tetrahydrobiopterin-free neuronal nitric oxide synthase: evidence for two identical highly anticooperative pteridine binding sites. Biochemistry 1996, 35(51):16735-16745.
53. Gorren A.C., et al. Low-temperature optical absorption spectra suggest a redox role for tetrahydrobiopterin in both steps of nitric oxide synthase catalysis. Biochemistry 2000, 39(38):11763-11770.
54. Griffith T.M., et al. 5-Methyltetrahydrofolate and tetrahydrobiopterin can modulate electrotonically mediated endothelium-dependent vascular relaxation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(19):7008-7013.
55. Harada T., Kagamiyama H., Hatakeyama K. Feedback regulation mechanisms for the control of GTP cyclohydrolase I activity. Science 1993, 260(5113):1507-1510.
56. Hattori Y., et al. Tetrahydrobiopterin and GTP cyclohydrolase I in a rat model of endotoxic shock: relation to nitric oxide synthesis. Exp. Physiol. 1996, 81(4):665-671.
57. Hattori Y., et al. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23(2):176-182.
58. Hattori Y., et al. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27(4):865-870.
59. He X., Su F., Velissaris D., Salgado D.R., Barros Dde S., Lorent S., Taccone F.S., Vincent J.L., De Backer D. Administration of tetrahydrobiopterin improves the microcirculation and outcome in an ovine model of septic shock*. Crit Care Med. 2012, 40:2833-2840.
60. Heitzer T., et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia 2000, 43(11):1435-1438.
61. Heitzer T., et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ. Res. 2000, 86(2):E36-E41.
62. Hesslinger C., et al. Phosphorylation of GTP cyclohydrolase I and modulation of its activity in rodent mast cells. GTP cyclohydrolase I hyperphosphorylation is coupled to high affinity IgE receptor signaling and involves protein kinase C. J. Biol. Chem. 1998, 273(34):21616-21622.
63. Higashi Y., et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am. J. Hypertens. 2002, 15(4 Pt. 1):326-332.
64. Higashi Y., et al. Tetrahydrobiopterin improves aging-related impairment of endothelium-dependent vasodilation through increase in nitric oxide production. Atherosclerosis 2006, 186(2):390-395.
65. Higgins C.E., Gross S.S. The N-terminal peptide of mammalian GTP cyclohydrolase I is an autoinhibitory control element and contributes to binding the allosteric regulatory protein GFRP. J. Biol. Chem. 2011, 286(14):11919-11928.
66. Hirooka Y., et al. Vitamin C improves attenuated angiotensin II-induced endothelium-dependent vasodilation in human forearm vessels. Hypertens. Res. 2003, 26(12):953-959.
67. Hong H.J., et al. Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 2001, 38(5):1044-1048.
68. Hoshiai K., et al. Increased plasma tetrahydrobiopterin in septic shock is a possible therapeutic target. Pathophysiol. 2001, 7(4):275-281.
69. Huang A., et al. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J. Biol. Chem. 2000, 275(23):17399-17406.
70. Ichinose H., et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat. Genet. 1994, 8(3):236-242.
71. Imazumi K., et al. Identification of a rabphilin-3A-interacting protein as GTP cyclohydrolase I in PC12 cells. Biochem. Biophys. Res. Commun. 1994, 205(2):1409-1416.
72. Ishii M., et al. Stimulation of tetrahydrobiopterin synthesis induced by insulin: possible involvement of phosphatidylinositol 3-kinase. Int. J. Biochem. Cell Biol. 2001, 33(1):65-73.
73. Jubb, H., et al., Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol Sci. 33(5): p. 241-8.
74. Kase H., et al. Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress. J. Hypertens. 2005, 23(7):1375-1382.
75. Katusic Z.S., Stelter A., Milstien S. Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 1998, 18(1):27-32.
76. Katusic Z.S., d'Uscio L.V., Nath K.A. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol. Sci. 2009, 30(1):48-54.
77. Kaufman S. The structure of the phenylalanine-hydroxylation cofactor. Proc. Natl. Acad. Sci. U. S. A. 1963, 50:1085-1093.
78. Kaufman S., et al. Hyperphenylalaninemia due to a deficiency of biopterin. A variant form of phenylketonuria. N. Engl. J. Med. 1978, 299(13):673-679.
79. Khoo J.P., et al. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation 2005, 111(16):2126-2133.
80. Klatt P., et al. Inhibitors of brain nitric oxide synthase. Binding kinetics, metabolism, and enzyme inactivation. J. Biol. Chem. 1994, 269(3):1674-1680.
81. Klatt P., et al. Structural analysis of porcine brain nitric oxide synthase reveals a role for tetrahydrobiopterin and l-arginine in the formation of an SDS-resistant dimer. EMBO J. 1995, 14(15):3687-3695.
82. Klemm P., et al. Inhibition by N-acetyl-5-hydroxytryptamine of nitric oxide synthase expression in cultured cells and in the anaesthetized rat. Br. J. Pharmacol. 1995, 115(7):1175-1181.
83. Kolinsky M.A., Gross S.S. The mechanism of potent GTP cyclohydrolase I inhibition by 2,4-diamino-6-hydroxypyrimidine: requirement of the GTP cyclohydrolase I feedback regulatory protein. J. Biol. Chem. 2004, 279(39):40677-40682.
84. Kosmicki M.A. Long-term use of short- and long-acting nitrates in stable angina pectoris. Curr. Clin. Pharmacol. 2009, 4(2):132-141.
85. Krishnakumar S., et al. Functional interactions between GTP cyclohydrolase I and tyrosine hydroxylase in Drosophila. J. Neurogenet. 2000, 14(1):1-23.
86. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(11):4651-4655.
87. Kunuthur S.P., et al. Tetrahydrobiopterin analogues with NO-dependent pulmonary vasodilator properties. Eur. J. Pharmacol. 2011, 650(1):371-377.
88. Kuzkaya N., et al. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J. Biol. Chem. 2003, 278(25):22546-22554.
89. Kwon N.S., Nathan C.F., Stuehr D.J. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J. Biol. Chem. 1989, 264(34):20496-20501.
90. Lapize C., et al. Protein kinase C phosphorylates and activates GTP cyclohydrolase I in rat renal mesangial cells. Biochem. Biophys. Res. Commun. 1998, 251(3):802-805.
91. Laursen J.B., et al. Endothelial regulation of vasomotion in ApoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103(9):1282-1288.
92. Lavoie A., et al. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am. J. Respir. Crit. Care Med. 1996, 153(6 Pt. 1):1985-1987.
93. Leeming R.J., et al. Biopterin derivatives in normal and phenylketonuric patients after oral loads of l-phenylalanine, l-tyrosine, and l-tryptophan. Arch. Dis. Child. 1976, 51(10):771-777.
94. Leiper J., Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat. Rev. Drug Discov. 2011, 10(4):277-291.
95. Leiper J., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat. Med. 2007, 13(2):198-203.
96. Lerman A., et al. Long-term l-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998, 97(21):2123-2128.
97. Li H.Y., et al. Effect of 2,4-diamino-6-hydroxy-pyrimidine on postburn Staphylococcus aureus sepsis in rats. Crit. Care Med. 2002, 30(11):2520-2527.
98. Li L., et al. A novel high-throughput screening assay for discovery of molecules that increase cellular tetrahydrobiopterin. J. Biomol. Screen. 2011, 16(8):836-844.
99. Li, L., et al., GTP cyclohydrolase I phosphorylation and interaction with GTP cyclohydrolase feedback regulatory protein provide novel regulation of endothelial tetrahydrobiopterin and nitric oxide. Circ Res. 106(2): p. 328-36.
100. Liao S.J., et al. Endothelium-targeted transgenic GTP-cyclohydrolase I overexpression inhibits neointima formation in mouse carotid artery. Clin. Exp. Pharmacol. Physiol. 2007, 34(12):1260-1266.
101. Liao Y.F., et al. Association of a functional polymorphism (C59038T) in GTP cyclohydrolase 1 gene and type 2 diabetic macrovascular disease in the Chinese population. J. Diabetes Complications 2010, 24(5):313-319.
102. Longo N. Disorders of biopterin metabolism. J. Inherit. Metab. Dis. 2009, 32(3):333-342.
103. Lopez A., et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 2004, 32(1):21-30.
104. Loscalzo J. Endothelial injury, vasoconstriction, and its prevention. Tex. Heart Inst. J. 1995, 22(2):180-184.
105. Maier W., et al. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J. Cardiovasc. Pharmacol. 2000, 35(2):173-178.
106. Maita N., et al. Crystal structure of the stimulatory complex of GTP cyclohydrolase I and its feedback regulatory protein GFRP. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(3):1212-1217.
107. Maita N., et al. Structural basis of biopterin-induced inhibition of GTP cyclohydrolase I by GFRP, its feedback regulatory protein. J. Biol. Chem. 2004, 279(49):51534-51540.
108. Marshall J.J., Kontos H.A. Endothelium-derived relaxing factors. A perspective from in vivo data. Hypertension 1990, 16(4):371-386.
109. Mayahi L., et al. (6R)-5,6,7,8-tetrahydro-l-biopterin and its stereoisomer prevent ischemia reperfusion injury in human forearm. Arterioscler. Thromb. Vasc. Biol. 2007, 27(6):1334-1339.
110. McDonald J.D., Bode V.C. Hyperphenylalaninemia in the hph-1 mouse mutant. Pediatr. Res. 1988, 23(1):63-67.
111. Meininger C.J., et al. GTP cyclohydrolase I gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats. FASEB J. 2004, 18(15):1900-1902.
112. Milstien S., Kaufman S. Tetrahydro-sepiapterin is an intermediate in tetrahydrobiopterin biosynthesis. Biochem. Biophys. Res. Commun. 1983, 115(3):888-893.
113. Mitchell B.M., Dorrance A.M., Webb R.C. GTP cyclohydrolase 1 inhibition attenuates vasodilation and increases blood pressure in rats. Am. J. Physiol. Heart Circ. Physiol. 2003, 285(5):H2165-H2170.
114. Mitchell B.M., Dorrance A.M., Webb R.C. Phenylalanine improves dilation and blood pressure in GTP cyclohydrolase inhibition-induced hypertensive rats. J. Cardiovasc. Pharmacol. 2004, 43(6):758-763.
115. Mittermayer F., et al. Tetrahydrobiopterin corrects Escherichia coli endotoxin-induced endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2005, 289(4):H1752-H1757.
116. Moens A.L., et al. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 2008, 294(5):H1971-H1977.
117. Moens A.L., et al. Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure. J. Mol. Cell. Cardiol. 2011, 51(4):564-569.
118. Moens A.L., et al. Targeting endothelial and myocardial dysfunction with tetrahydrobiopterin. J. Mol. Cell. Cardiol. 2011, 51(4):559-563.
119. Moreau K.L., et al. Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. Am. J. Physiol. Heart Circ. Physiol. 2012, 302(5):H1211-H1218.
120. Muntau A.C., et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med. 2002, 347(26):2122-2132.
121. Murray H.W., Nathan C.F. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 1999, 189(4):741-746.
122. Nagatsu T., Levitt M., Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J. Biol. Chem. 1964, 239:2910-2917.
123. Nandi M., et al. Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse. Circulation 2005, 111(16):2086-2090.
124. Nandi M., et al. Developmental regulation of GTP-CH1 in the porcine lung and its relationship to pulmonary vascular relaxation. Pediatr. Res. 2006, 59(6):767-772.
125. Nandi M., et al. Over-expression of GTP-cyclohydrolase 1 feedback regulatory protein attenuates LPS and cytokine-stimulated nitric oxide production. Vasc. Med. 2008, 13(1):29-36.
126. Naylor, A.M., et al., The tetrahydrobiopterin pathway and pain. Curr. Opin. Investig. Drugs. 11(1) 19-30.
127. Ness A., Egger M., Smith G.D. Role of antioxidant vitamins in prevention of cardiovascular diseases. Meta-analysis seems to exclude benefit of vitamin C supplementation. BMJ 1999, 319(7209):577.
128. Neville B.G., et al. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 2005, 128(Pt. 10):2291-2296.
129. Niederwieser A., et al. GTP cyclohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia. Eur. J. Pediatr. 1984, 141(4):208-214.
130. Nystrom T., Nygren A., Sjoholm A. Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. Am. J. Physiol. Endocrinol. Metab. 2004, 287(5):E919-E925.
131. Ohashi A., et al. Membrane transport of sepiapterin and dihydrobiopterin by equilibrative nucleoside transporters: a plausible gateway for the salvage pathway of tetrahydrobiopterin biosynthesis. Mol. Genet. Metab. 2011, 102(1):18-28.
132. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327(6122):524-526.
133. Panda K., et al. Distinct dimer interaction and regulation in nitric-oxide synthase types I, II, and III. J. Biol. Chem. 2002, 277(34):31020-31030.
134. Pieper G.M. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J. Cardiovasc. Pharmacol. 1997, 29(1):8-15.
135. Porkert M., et al. Tetrahydrobiopterin: a novel antihypertensive therapy. J. Hum. Hypertens. 2008, 22(6):401-407.
136. Presta A., et al. Comparative functioning of dihydro- and tetrahydropterins in supporting electron transfer, catalysis, and subunit dimerization in inducible nitric oxide synthase. Biochemistry 1998, 37(1):298-310.
137. Rebelo J., et al. Biosynthesis of pteridines. Reaction mechanism of GTP cyclohydrolase I. J. Mol. Biol. 2003, 326(2):503-516.
138. Robbins I.M., et al. Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp. Lung Res. 2011, 37(1):26-34.
139. Rossiter S., et al. Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase. J. Med. Chem. 2005, 48(14):4670-4678.
140. Saunders-Pullman R., et al. Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test. Mol. Genet. Metab. 2004, 83(3):207-212.
141. Sawabe K., Wakasugi K.O., Hasegawa H. Tetrahydrobiopterin uptake in supplemental administration: elevation of tissue tetrahydrobiopterin in mice following uptake of the exogenously oxidized product 7,8-dihydrobiopterin and subsequent reduction by an anti-folate-sensitive process. J. Pharmacol. Sci. 2004, 96(2):124-133.
142. Schmidt K., et al. Preferential inhibition of inducible nitric oxide synthase in intact cells by the 4-amino analogue of tetrahydrobiopterin. Eur. J. Biochem. 1999, 259(1-2):25-31.
143. Schmidt P.P., et al. Formation of a protonated trihydrobiopterin radical cation in the first reaction cycle of neuronal and endothelial nitric oxide synthase detected by electron paramagnetic resonance spectroscopy. J. Biol. Inorg. Chem. 2001, 6(2):151-158.
144. Schmidt T.S., et al. Tetrahydrobiopterin supplementation reduces atherosclerosis and vascular inflammation in apolipoprotein E-knockout mice. Clin. Sci. (Lond.) 2010, 119(3):131-142.
145. Schoedon G., et al. Modulation of human endothelial cell tetrahydrobiopterin synthesis by activating and deactivating cytokines: new perspectives on endothelium-derived relaxing factor. Biochem. Biophys. Res. Commun. 1993, 196(3):1343-1348.
146. Schoedon G., et al. Nitric oxide production depends on preceding tetrahydrobiopterin synthesis by endothelial cells: selective suppression of induced nitric oxide production by sepiapterin reductase inhibitors. Biochem. Biophys. Res. Commun. 1994, 199(2):504-510.
147. Setoguchi S., et al. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J. Am. Coll. Cardiol. 2001, 38(2):493-498.
148. Seujange Y., Eiam-Ong S., Tirawatnapong T. Role of angiotensin II on dihydrofolate reductase, GTP-cyclohydrolase 1 and nitric oxide synthase expressions in renal ischemia-reperfusion. Am. J. Nephrol. 2008, 28(4):692-700.
149. Shimokawa H. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pflugers Arch. 2010, 459(6):915-922.
150. Shinozaki K., et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ. Res. 2000, 87(7):566-573.
151. Simmons W.W., et al. Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and l-arginine transport. J. Biol. Chem. 1996, 271(39):23928-23937.
152. Storm C.B., Kaufman S. The effect of variation of cofactor and substrate structure on the action of phenylalanine hydroxylase. Biochem. Biophys. Res. Commun. 1968, 32(5):788-793.
153. Stroes E., et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest. 1997, 99(1):41-46.
154. Stuehr D.J., et al. N omega-hydroxy-l-arginine is an intermediate in the biosynthesis of nitric oxide from l-arginine. J. Biol. Chem. 1991, 266(10):6259-6263.
155. Suckling C.J., et al. 6-Acetyl-7,7-dimethyl-5,6,7,8-tetrahydropterin is an activator of nitric oxide synthases. Bioorg. Med. Chem. Lett. 2008, 18(5):1563-1566.
156. Sun T., et al. Oral l-arginine supplementation in acute myocardial infarction therapy: a meta-analysis of randomized controlled trials. Clin. Cardiol. 2009, 32(11):649-652.
157. Sun X., et al. Estradiol increases GTP cyclohydrolase expression via the nitric oxide mediated activation of camp response element binding protein. Endocrinology 2009.
158. Sun X., et al. C-terminus of heat shock protein 70-interacting protein-dependent GTP cyclohydrolase I degradation in lambs with increased pulmonary blood flow. Am. J. Respir. Cell Mol. Biol. 2011, 45(1):163-171.
159. Swick L., Kapatos G. A yeast 2-hybrid analysis of human GTP cyclohydrolase I protein interactions. J. Neurochem. 2006, 97(5):1447-1455.
160. Takeda M., et al. Plasma tetrahydrobiopterin/dihydrobiopterin ratio: a possible marker of endothelial dysfunction. Circ. J. 2009, 73(5):955-962.
161. Tatham A.L., et al. GTP cyclohydrolase I expression, protein, and activity determine intracellular tetrahydrobiopterin levels, independent of GTP cyclohydrolase feedback regulatory protein expression. J. Biol. Chem. 2009, 284(20):13660-13668.
162. Tayeh M.A., Marletta M.A. Macrophage oxidation of l-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J. Biol. Chem. 1989, 264(33):19654-19658.
163. Tegeder I., et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat. Med. 2006, 12(11):1269-1277.
164. Teng R.J., et al. Sepiapterin improves angiogenesis of pulmonary artery endothelial cells with in utero pulmonary hypertension by recoupling endothelial nitric oxide synthase. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 301(3):L334-L345.
165. Thony B., Auerbach G., Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 2000, 347(Pt. 1):1-16.
166. Tietz A., Lindberg M., Kennedy E.P. A new pteridine-requiring enzyme system for the oxidation of glyceryl ethers. J. Biol. Chem. 1964, 239:4081-4090.
167. Tousoulis D., et al. Effects of vitamin C on intracoronary l-arginine dependent coronary vasodilatation in patients with stable angina. Heart 2005, 91(10):1319-1323.
168. Trefz F.K., et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J. Pediatr. 2009, 154(5):700-707.
169. Trzeciak S., McCoy J.V., Phillip Dellinger R., Arnold R.C., Rizzuto M., Abate N.L., Shapiro N.I., Parrillo J.E., Hollenberg S.M. Early increases in microcirculatory perfusion during protocoldirected resuscitation are associated with reduced multi-organ failure at 24h in patients with sepsis. Intensive Care Med. 2008, 34:2210-2217.
170. Ueda S., et al. Tetrahydrobiopterin restores endothelial function in long-term smokers. J. Am. Coll. Cardiol. 2000, 35(1):71-75.
171. Vasquez-Vivar J., et al. Reaction of tetrahydrobiopterin with superoxide: EPR-kinetic analysis and characterization of the pteridine radical. Free Radic. Biol. Med. 2001, 31(8):975-985.
172. Vasquez-Vivar J., et al. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochem. J. 2002, 362(Pt. 3):733-739.
173. Vasquez-Vivar J., et al. Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler. Thromb. Vasc. Biol. 2002, 22(10):1655-1661.
174. Walter R., et al. Induction of tetrahydrobiopterin synthesis in human umbilical vein smooth muscle cells by inflammatory stimuli. Immunol. Lett. 1998, 60(1):13-17.
175. Wang S., et al. Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension 2008, 52(3):484-490.
176. Watschinger K., et al. Identification of the gene encoding alkylglycerol monooxygenase defines a third class of tetrahydrobiopterin-dependent enzymes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(31):13672-13677.
177. Watson D., et al. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit. Care Med. 2004, 32(1):13-20.
178. Wei C.C., et al. A tetrahydrobiopterin radical forms and then becomes reduced during Nomega-hydroxyarginine oxidation by nitric-oxide synthase. J. Biol. Chem. 2003, 278(47):46668-46673.
179. Wei C.C., et al. Structure of tetrahydrobiopterin tunes its electron transfer to the heme-dioxy intermediate in nitric oxide synthase. Biochemistry 2003, 42(7):1969-1977.
180. Wei C.C., et al. Catalytic reduction of a tetrahydrobiopterin radical within nitric-oxide synthase. J. Biol. Chem. 2008, 283(17):11734-11742.
181. Wells J.A., McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450(7172):1001-1009.
182. Werner E.R., Werner-Felmayer G. Biopterin analogues: novel nitric oxide synthase inhibitors with immunosuppressive action. Curr. Drug Metab. 2002, 3(2):119-121.
183. Werner E.R., et al. Bacterial lipopolysaccharide down-regulates expression of GTP cyclohydrolase I feedback regulatory protein. J. Biol. Chem. 2002, 277(12):10129-10133.
184. Werner E.R., Blau N., Thony B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem. J. 2011, 438(3):397-414.
185. Werner-Felmayer G., et al. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J. Biol. Chem. 1993, 268(3):1842-1846.
186. Werner-Felmayer G., Golderer G., Werner E.R. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr. Drug Metab. 2002, 3(2):159-173.
187. Widder J.D., et al. Regulation of tetrahydrobiopterin biosynthesis by shear stress. Circ. Res. 2007, 101(8):830-838.
188. Wilson A.M., et al. l-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007, 116(2):188-195.
189. Worthley M.I., et al. Effects of tetrahydrobiopterin on coronary vascular reactivity in atherosclerotic human coronary arteries. Cardiovasc. Res. 2007, 76(3):539-546.
190. Wyss C.A., et al. Tetrahydrobiopterin restores impaired coronary microvascular dysfunction in hypercholesterolaemia. Eur. J. Nucl. Med. Mol. Imaging 2005, 32(1):84-91.
191. Xia T., Gray D.W., Shiman R. Regulation of rat liver phenylalanine hydroxylase. III. Control of catalysis by (6R)-tetrahydrobiopterin and phenylalanine. J. Biol. Chem. 1994, 269(40):24657-24665.
192. Yamashiro S., et al. Role of tetrahydrobiopterin on ischemia-reperfusion injury in isolated perfused rat hearts. J. Cardiovasc. Surg. (Torino) 2003, 44(1):37-49.
193. Yoneyama T., Hatakeyama K. Decameric GTP cyclohydrolase I forms complexes with two pentameric GTP cyclohydrolase I feedback regulatory proteins in the presence of phenylalanine or of a combination of tetrahydrobiopterin and GTP. J. Biol. Chem. 1998, 273(32):20102-20108.
194. Yoneyama T., Hatakeyama K. Ligand binding to the inhibitory and stimulatory GTP cyclohydrolase I/GTP cyclohydrolase I feedback regulatory protein complexes. Protein Sci. 2001, 10(4):871-878.
195. Zhang L., et al. Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J. Clin. Invest. 2007, 117(9):2658-2671.
196. Zschocke J. Phenylketonuria mutations in Europe. Hum. Mutat. 2003, 21(4):345-356.